X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to develop a novel HIV vaccine candidate that will be composed of ReiThera’s Gorilla adenoviral vector (GRAd) and HIV T cell epitopes identified by the Ragon Institute.
Lead Product(s): GRAd-HIV Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: The Ragon Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 22, 2024
Details:
The Phase 1 clinical trial is evaluating the safety and immunogenicity of GRAd-COV2 in 90 healthy volunteers with an objective to select a vaccine dose for further investigation in a Phase 2/3 trial.
Lead Product(s): GRAd-COV2
Therapeutic Area: Infections and Infectious Diseases Product Name: GRAd-COV2
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020
Details:
This new funding from BARDA will enable Sabin and ReiThera to advance the investigational Ebola Sudan and Marburg vaccines through GMP manufacturing and release of ChAd3-MARV and ChAd3-SUDV Phase 2 clinical trial.
Lead Product(s): ChAd3-SUDV
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: BARDA
Deal Size: $215.5 million Upfront Cash: Undisclosed
Deal Type: Funding May 13, 2020
Details:
The pan-European consortium of ReiThera, LEUKOCARE and Univercells brings together an adenoviral vector-based vaccine candidate targeting the spike protein of SARS-CoV-2.
Lead Product(s): Adenoviral vector-based vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Univercells
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 23, 2020
Details:
The vaccine developed by ReiThera has been obtained from a fragment of the genetic material of the virus and is based on the technology called electroporation.
Lead Product(s): Covid-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
